ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented At Leading Symposium On Anti-Angiogenic Agents
Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical
company developing monoclonal antibodies for the treatment of cancer and
hepatitis C virus infection (HCV), reported that clinical data on its
anti-phosphatidylserine (anti-PS) monoclonal antibody bavituximab was
discussed at the 10th Annual International Symposium on Anti-Angiogenic
Agents (Angio 2008) in La Jolla, CA.
Bavituximab is a monoclonal antibody that binds to a phospholipid
called phosphatidylserine that is usually located inside normal cells, but
which becomes exposed on the outside of the cells that line the blood
vessels of tumors, creating a specific target for anti-cancer treatments.
Peregrine recently initiated its Phase II clinical cancer program for
bavituximab.
Alison T. Stopeck, M.D., associate professor of medicine, Department of
Medicine, Cancer Center Division at the University of Arizona College of
Medicine in Tucson, and team leader of the Breast Cancer Team, Arizona
Cancer Center, presented clinical data on bavituximab as part of an Angio
2008 Symposium panel. Dr. Stopeck is an investigator in an ongoing Phase I
study that is assessing bavituximab as monotherapy in patients with
advanced solid cancers. She also discussed data from a Phase Ib combination
therapy cancer trial that was completed last year and from two Phase I
clinical trials testing bavituximab in patients with chronic hepatitis C
virus infections.
"Bavituximab has a unique anti-vascular mechanism of action and early
trials of its use in more than 80 patients as a single agent and in
combination therapy cancer studies, and as monotherapy in patients with
HCV, have demonstrated a predictable and acceptable safety profile that is
consistent with preclinical predictions," said Dr. Stopeck. "I look forward
to helping to advance the clinical program for this novel approach to
cancer therapy."
Bavituximab is believed to help mobilize the body's immune system to
destroy the blood vessels needed for tumor growth and spread. Preclinical
studies have shown that bavituximab's PS target is upregulated by radiation
and chemotherapy, suggesting that anti-PS agents are good candidates for
use as part of combination therapy regimens. The approach has demonstrated
encouraging anti-tumor activity as part of combination therapy regimens in
a number of solid tumor models.
"We are delighted that Dr. Stopeck is presenting early clinical data on
bavituximab at this important scientific meeting," said Steven W. King,
president and CEO of Peregrine. "As we move to assess bavituximab in Phase
II efficacy trials, we are eager to share with the broader scientific and
medical communities the growing body of data supporting the positive safety
profile and signs of anti-tumor and anti-viral effects demonstrated by this
exciting new class of drugs in both single agent and combination therapy
studies."
In a Phase Ib pilot trial in advanced cancer patients, bavituximab plus
chemotherapy appeared to have a safety profile consistent with chemotherapy
alone and showed positive signs of clinical activity in a number of tumor
types, achieving objective response or disease stabilization in 50% of the
evaluable patients. Peregrine recently received regulatory approval to
conduct three Phase II trials to study the anti-tumor effects of
bavituximab in combination with chemotherapy. These include two breast
cancer protocols and a non-small cell lung cancer (NSCLC) protocol. One of
the breast cancer trials has begun enrolling patients and the two other
trials are expected to begin soon. Bavituximab is also in clinical trials
in the U.S. in patients co-infected with HCV and HIV.
Dr. Stopeck's presentation, "Phase I Clinical Studies of the Anti-Tumor
Vasculature Antibody, Bavituximab," is part of the Angio 2008 session on
Early Drug Development/Clinical Trial Results being held from 8:00 am to
12:00 pm PST at the 10th Annual International Symposium on Anti-Angiogenic
Agents at the Hyatt Regency Hotel in La Jolla, CA.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative product candidates in clinical trials for the
treatment of cancer and hepatitis C virus (HCV) infection. The company is
pursuing three separate clinical programs in cancer and HCV infection with
its lead product candidates bavituximab and Cotara(R). Peregrine also has
in-house manufacturing capabilities through its wholly owned subsidiary
Avid Bioservices, Inc. (http://www.avidbio.com), which provides development
and bio-manufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
http://www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not
purely historical, including statements regarding Peregrine
Pharmaceuticals' intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements involve risks and uncertainties
including, but not limited to, the risk that results of future clinical
trials will not correlate with the results of earlier phase I trials and
preclinical studies. It is important to note that the company's actual
results could differ materially from those in any such forward-looking
statements. Factors that could cause actual results to differ materially
include, but are not limited to, uncertainties associated with completing
preclinical and clinical trials for our technologies; the early stage of
product development; the significant costs to develop our products as all
of our products are currently in development, preclinical studies or
clinical trials; obtaining additional financing to support our operations
and the development of our products; obtaining regulatory approval for our
technologies; anticipated timing of regulatory filings and the potential
success in gaining regulatory approval and complying with governmental
regulations applicable to our business. Our business could be affected by a
number of other factors, including the risk factors listed from time to
time in the company's SEC reports including, but not limited to, the annual
report on Form 10-K for the year ended April 30, 2007 and the quarterly
report on Form 10-Q for the quarter ended October 31, 2007. The company
cautions investors not to place undue reliance on the forward-looking
statements contained in this press release. Peregrine Pharmaceuticals, Inc.
disclaims any obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
Peregrine Pharmaceuticals, Inc.
http://www.peregrineinc.com
Experienþa clinicã cu strãin de anti-cancer agent Bavituximab prezentate la Simpozionul de pe frunte Angiogenic agenþi anti - - Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented At Leading Symposium On Anti-Angiogenic Agents - articole medicale engleza - startsanatate